Navigation Links
Generic Drug Decision Disastrous to Patient Safety
Date:6/23/2011

WASHINGTON, June 23, 2011 /PRNewswire-USNewswire/ -- Today's U.S. Supreme Court decision in Pliva v. Mensing is a disastrous outcome for patient safety, giving generic drug companies legal immunity when they ignore harmful side-effects of the drugs they manufacture and profit from.  This decision eliminates any incentive for generic manufacturers to ensure their drug is safe and adequately warn consumers of their drugs' potential dangers.

This decision also means that brand-name manufacturers will be held to a different yet safer standard.  The Supreme Court decided in Wyeth v. Levine, brand-name manufacturers are responsible for their warning labels and required to update them at all times.  

"Patients will now be taking generic drugs at their own risk," said American Association for Justice President Gibson Vance. "It is absurd that doctors and patients will have to make medical decisions knowing that only brand-name drug manufacturers – not generics – can be held accountable for their drugs' dangerous side-effects."

Today, 70 percent of all prescription drugs are filled with generic versions, accounting for about 2.6 billion prescriptions every year.  Additionally, the generic drug industry continues to expand – nine of the industry's 10 biggest blockbuster drugs are going off-patent within in the next few years. 

"Congress and the Food and Drug Administration need to quickly address the huge legal disparity between brand-name and generic drugs," said Vance.  "Today's decision sends a dangerous and expensive message to patients: you are safer taking brand-name drugs."

Louis Bograd, Senior Litigation Counsel at the Center for Constitutional Litigation, argued this case on behalf of Mensing, and AAJ also filed an amicus brief.  For more information, visit www.justice.org/courts.  To speak with counsel or parties in Pliva v. Mensing, contact Jennifer.Fuson@justice.org, 202-944-2896.Drugs Expected to Come off Patent in the United States by Year:2011

2012

2014Actos

Plavix

Lexapro

CelebrexCozaar

Seroquel

Singulair

CymbaltaConcerta

Valtrex

Viagra

NexiumEffexor

ZyPrexaRisperdalFlomaxSymbicortImitrexLevaquinLipitorLotrelAs the world's largest trial bar, the American Association for Justice (formerly known as the Association of Trial Lawyers of America) works to make sure people have a fair chance to receive justice through the legal system when they are injured by the negligence or misconduct of others--even when it means taking on the most powerful corporations. Visit http://www.justice.org.


'/>"/>
SOURCE American Association for Justice
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lupin Announces Launch of Generic Levaquin® Tablets
2. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
3. Watson Confirms Court Decision Rejecting Tevas Motion to Prevent Launch of Generic SEASONIQUE®
4. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
5. HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer
6. Breckenridge Announces Approval of Generic Activella® 0.5mg/0.1mg Tablets
7. Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products
8. Mylan Receives Approval for Generic Version of Aricept® Tablets
9. Mylan Receives Approval for Generic Version of Effexor XR® Capsules
10. Reportlinker Adds Generic Pharmaceuticals Industry - Top 200 Generic Pharmaceuticals Industry (Global)
11. Mylan Launches Generic Version of Roxicodone® Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... 2017 Research and Markets has announced the ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ... ... will rise from USD 20 Billion in 2015 to around USD ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... ... an agile ecosystem and domain expertise for sponsors and CROs to speed ... trial supply management (RTSM) software platform. Bioclinica AGILE RTSM provides ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , ... . This new addition to the Mirroring360 product family combines device screen mirroring ... Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror app ...
(Date:4/25/2017)... NY (PRWEB) , ... April 25, 2017 , ... A ... stress at work can also decrease overall productivity and performance in the workplace. The ... employees. , During the last few weeks of April, Clearview Resolution Services will be ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... rely on contracted partners to help with process innovation in drug formulation and ... formulation experience along with state-of-the-art analytical equipment in support of their development and ...
Breaking Medicine News(10 mins):